The current invention relates to the discovering that specified DPP-4 inhibitors are particularly suited to dealing with and/or protecting against metabolic health conditions, specifically diabetes, in individuals for whom metformin therapy is inappropriate as a consequence of intolerability or contraindication in opposition to metformin. Remark: The SAVOR- TIMI fifty https://semaglutidemanufacturer97531.bleepblogs.com/24086975/fascination-about-generic-linagliptin-india